One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes
Jacqueline Saw, MD, a Andrew Starovoytov, MD, a Eve Aymong, MD,b Taku Inohara, MD,a Mesfer Alfadhel, MD, a Cameron McAlister, MD,a Rohit Samuel, MD, a Tejana Grewal, MD,a Johandra Argote Parolis, MD, a Tej Sheth, MD,c Derek So, MD,d Kunal Minhas, MD, e Neil Brass, MD,f Andrea Lavoie, MD, g Helen Bishop, MD, h Shahar Lavi, MD, i Colin Pearce, MD, j Suzanne Renner, MD,k Mina Madan, MD, l Robert C. Welsh, MD,m Brent M. McGrath, MD, PHD, n Ram Vijayaraghavan, MD,o Bryan Har, MD, p Reda Ibrahim, MD, q Pulkit Chaudhary, MD, r Santhi K. Ganesh, MD, s John Graham, MD, t Alexis Matteau, MD,u Giuseppe Martucci, MD,v Dennis T. Ko, MD, MS C,l Karin Humphries, DSC, w GB John Mancini, MD
doi : 10.1016/j.jacc.2022.08.759
Volume 80, Issue 17, 25 October 2022, Pages 1585-1597
Spontaneous coronary artery dissection (SCAD) is an important cause of myocardial infarction (MI) in young to middle-aged women.
Spontaneous coronary artery dissection (SCAD) is an important cause of myocardial infarction (MI) in young to middle-aged women.
Alexandre Persu, MD, PH D, a,b David Adlam, BA, BM BC H , DPHIL, c Jeffrey W. Olin, DO
doi : 10.1016/j.jacc.2022.09.004
Volume 80, Issue 17, 25 October 2022, Pages 1598-1600
Impact of Periprocedural Pulmonary Hypertension on Outcomes After Transcatheter Aortic Valve Replacement
Junichi Miyamoto, MD,a Yohei Ohno, MD,a Norihiko Kamioka, MD, a Yuji Ikari, MD, a Toshiaki Otsuka, MD, b Norio Tada, MD, c Toru Naganuma, MD,d Masahiro Yamawaki, MD,e Futoshi Yamanaka, MD, f Shinichi Shirai, MD,g Kazuki Mizutani, MD,h Minoru Tabata, MD,i Hiroshi Ueno, MD, j Kensuke Takagi, MD,k Yusuke Watanabe, MD, l Masanori Yamamoto, MD, m Kentaro Hayashida, MD,n on behalf of the OCEAN-TAVI Investigators
doi : 10.1016/j.jacc.2022.08.757
Volume 80, Issue 17, 25 October 2022, Pages 1601-1613
There are limited data on the prognostic impact of periprocedural pulmonary hypertension (PH) after transcatheter aortic valve replacement (TAVR).
Pulmonary Hypertension and Aortic Stenosis: A Piece of the Puzzle
Philippe Généreux, MD
doi : 10.1016/j.jacc.2022.09.005
Volume 80, Issue 17, 25 October 2022, Pages 1614-1616
Noninvasive Physiologic Assessment of Cardiac Allograft Vasculopathy Is Prognostic for Post-Transplant Events
Kevin J. Clerkin, MD, MSC ,a Veli K. Topkara, MD, MSC ,a Maryjane A. Farr, MD, MS C, a Rashmi Jain, MD,a Paolo C. Colombo, MD, a Susan Restaino, MD,a Gabriel Sayer, MD,a Michelle Castillo, BS, a Elaine Y. Lam, PA-C, a Margarita Chernovolenko, MD, a Melana Yuzefpolskaya, MD, a Ersilia DeFilippis, MD,a Farhana Latif, MD, a Emmanuel Zorn, P HD, a Koji Takeda, MD, P HD, b Lynne L. Johnson, MD, a Nir Uriel, MD, MSC ,a Andrew J. Einstein, MD, P HD
doi : 10.1016/j.jacc.2022.08.751
Volume 80, Issue 17, 25 October 2022, Pages 1617-1628
Cardiac allograft vasculopathy (CAV) causes impaired blood flow in both epicardial coronary arteries and the microvasculature. A leading cause of post-transplant mortality, CAV affects 50% of heart transplant recipients within 10 years of heart transplant.
The Panvascular Interplay in Pathophysiology and Prognosis of Cardiac Allograft Vasculopathy∗
Mandeep R. Mehra, MD, MS C,a Jacinthe Boulet, MD, CM, MPH,a Matthieu Pelletier-Galarneau, MD, MSC
doi : 10.1016/j.jacc.2022.08.753
Volume 80, Issue 17, 25 October 2022, Pages 1629-1632
Circulating T Cells and Cardiovascular Risk in People With and Without HIVÂ Infection
Suman Kundu, DS C,a Matthew S. Freiberg, MD, MSC ,a,b Russell P. Tracy, P HD, c Kaku A. So-Armah, PH D, d John R. Koethe, MD,a,b Meredith S. Duncan, PH D, MA, a,e Hilary A. Tindle, MD, MPH,a Joshua A. Beckman, MD, MS C,a Matthew J. Feinstein, MD, MS C,f Wyatt J. McDonnell, P HD, g Amy Justice, MD, PHD, h,i Margaret F. Doyle, PHD, c on behalf of the Veterans Aging Cohort Study
doi : 10.1016/j.jacc.2022.08.756
Volume 80, Issue 17, 25 October 2022, Pages 1633-1644
Lower CD4+ cell count in people with HIV infection (PWH) is associated with increased cardiovascular disease (CVD) risk. Whether subsets of CD4+ T helper cells are linked with CVD is unclear.
CD4+ T Cell Subsets and Cardiovascular Disease in People With HIV∗
Marinos Kallikourdis, P HD, a,b Gianluigi Condorelli, MD, P HD
doi : 10.1016/j.jacc.2022.08.758
Volume 80, Issue 17, 25 October 2022, Pages 1645-1646
Diaphragmatic Function in Cardiovascular Disease: JACC Review Topic of the Week
Husam M. Salah, MD,a Lee R. Goldberg, MD, MPH,b Jeroen Molinger, MS, c G. Michael Felker, MD, MHS, c,d Willard Applefeld, MD, c Tienush Rassaf, MD, e Ryan J. Tedford, MD, f Michael Mirro, MD, g,h,i John G.F. Cleland, MD, j,k Marat Fudim, MD, MHS
doi : 10.1016/j.jacc.2022.08.760
Volume 80, Issue 17, 25 October 2022, Pages 1647-1659
In addition to the diaphragm’s role as the primary respiratory muscle, it also plays an under-recognized role in cardiac function. It serves as a pump facilitating venous and lymph return, modulating left ventricular afterload hemodynamics and pericardial pressures, as well as regulating autonomic tone.
2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards
doi : 10.1016/j.jacc.2022.05.012
Volume 80, Issue 17, 25 October 2022, Pages 1660-1700
Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillator Therapy in Patients With Tetralogy of Fallot
Victor Waldmann, MD, PhD Christelle Marquié, MD Abdeslam Bouzeman, MD Guillaume Duthoit, MD Jean-Benoit Thambo, MD, PhD Linda Koutbi, MD Alice Maltret, MD Jean-Luc Pasquié, MD, PhD Nicolas Combes, MD Eloi Marijon, MD, PhD
doi : 10.1016/j.jacc.2022.08.761
Volume 80, Issue 17, 25 October 2022, Pages 1701-1703
Poverty and Adverse Outcomes Among Patients With Chronic Cardiovascular Disease: What Is the Mechanism?
Akshay Pendyal, MD, MHS
doi : 10.1016/j.jacc.2022.07.029
Volume 80, Issue 17, 25 October 2022, Page e139
Reply: Poverty and Adverse Outcomes Among Patients With Chronic Cardiovascular Disease: What Is the Mechanism?
Magnus Dalén, MD, PhD Michael Persson, MD Natalie Glaser, MD, PhD Ulrik Sartipy, MD, PhD
doi : 10.1016/j.jacc.2022.08.755
Volume 80, Issue 17, 25 October 2022, Page e141
